Abstract
The development and animal testing of a bivalent influenza virus vaccine in immunologic adjuvant 65 employing a new highly purified viral antigen is described. The enhancement of serologic response to the highly purified viral antigen in adjuvant was as great as achieved heretofore with ordinary Sharpies or protamine-concentrated vaccines used with the adjuvant. Influenza vaccines in adjuvant 65 which were stored at 4°C for periods from 9 to 41 months retained their full antigenic potency and did not acquire toxicity as measured in the guinea pig dermal and mouse peritoneal toxicity assays. The new purified vaccine offers an advantage in reducing the amount of extraneous egg al-lantoic protein in the vaccine thereby affording less chance for allergic sensitization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
